The recent Combi-v [1] and Combi-d [2,3], phase III randomized trials, showed, respectively, an OS benefit with Dabrafenib/Trametinib combination versus Vemurafenib and an improvement in PFS and ORR with the same combination versus Dabrafenib alone, in BRAF V600E/K mutation positive metastatic or unresectable cutaneous melanoma. We report the case of a young patient with metastatic melanoma treated with anti- BRAF/antiMEK combination.
BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report / Giovannoni, Sara; Urbano, Federica; Modica, Daniela; Verkhovskaia, Sofia; Giuliana, Caprio; Mezi, Silvia; Cortesi, Enrico. - In: JOURNAL OF TRANSLATIONAL MEDICINE. - ISSN 1479-5876. - STAMPA. - 13:Suppl 1(2015), pp. 8-9. ((Intervento presentato al convegno Melanoma Bridge 2014 tenutosi a Napoli nel 3-6 dicembre 2014 [10.1186/1479-5876-13-S1-P8].
BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report
GIOVANNONI, SARA;URBANO, FEDERICA;MODICA, DANIELA;VERKHOVSKAIA, SOFIA;MEZI, Silvia;CORTESI, Enrico
2015
Abstract
The recent Combi-v [1] and Combi-d [2,3], phase III randomized trials, showed, respectively, an OS benefit with Dabrafenib/Trametinib combination versus Vemurafenib and an improvement in PFS and ORR with the same combination versus Dabrafenib alone, in BRAF V600E/K mutation positive metastatic or unresectable cutaneous melanoma. We report the case of a young patient with metastatic melanoma treated with anti- BRAF/antiMEK combination.| File | Dimensione | Formato | |
|---|---|---|---|
|
Giovannoni_Metastatic-melanoma_2015.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
455.77 kB
Formato
Adobe PDF
|
455.77 kB | Adobe PDF | Visualizza/Apri PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
